Core Viewpoint - Baiaosaitu-B (02315) has seen a significant stock price increase, with a rise of over 12% during trading, currently up 9.5% at HKD 25.12, with a trading volume of HKD 11.11 million. The company has received approval from the China Securities Regulatory Commission (CSRC) for its IPO application on the STAR Market, aiming to raise approximately RMB 1.185 billion for various projects and working capital [1]. Group 1 - The company plans to use RMB 454 million for the construction of an early drug research and development service platform [1]. - RMB 316 million is allocated for the research and evaluation of antibody drugs [1]. - RMB 165 million is designated for preclinical and clinical research projects [1]. - RMB 250 million will be used to supplement working capital [1]. Group 2 - Baiaosaitu has recently announced collaborations with Germany's Tubulis and global technology leader Merck [1]. - The partnership with Tubulis involves the introduction of Baiaosaitu's self-developed fully human antibodies to advance the development and commercialization of ADC products, with the company set to receive an upfront payment and potential milestone payments based on development, regulatory, and commercialization achievements, along with a single-digit percentage of net sales [1]. - The collaboration with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1].

Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock price increase following the approval of its IPO registration by the China Securities Regulatory Commission (CSRC) [1] Group 1: IPO Details - BaiO Saite plans to raise 1.185 billion yuan through its IPO, with allocations of 454 million yuan for early drug development service platform construction, 316 million yuan for antibody drug research and evaluation, 165 million yuan for preclinical and clinical research, and 250 million yuan for working capital [1] Group 2: Strategic Partnerships - The company has recently announced collaborations with Germany's Tubulis and global technology leader Merck. Tubulis aims to utilize BaiO Saite's self-developed fully human antibodies to advance its ADC product development and commercialization, providing BaiO Saite with an upfront payment and potential milestone payments along with a share of net sales [1] - The partnership with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1]

Group 1 - The core point of the article is that the China Securities Regulatory Commission has approved the registration application for the initial A-share issuance of Baiaosaitu-B (02315.HK) on October 15 [3] - The statement emphasizes that the proposed A-share issuance must meet several prerequisites, and therefore, it may not be completed [3] - Baiaosaitu was listed on the Hong Kong Stock Exchange on September 1, 2022, raising approximately HK$617 million during its IPO [3] Group 2 - As of the latest trading session, Baiaosaitu's stock price is reported at HK$23.04, with a market capitalization exceeding HK$9.2 billion [4] - The stock has experienced a 1.20% decrease, with a 52-week high of HK$31.34 and a low of HK$5.60 [4] - The company has an earnings per share of HK$0.36 and a net asset value per share of HK$2.45 [4]

Core Insights - The biotechnology sector in the Hong Kong stock market has shown strong performance, with several stocks experiencing significant gains today, particularly药捷安康-B which surged over 30% [1] Stock Performance Summary - 药捷安康-B: Increased by 31.25%, latest price at 218.000, total market value of 86.524 billion, year-to-date increase of 1557.79% [2] - 康宁杰瑞制药-B: Increased by 7.15%, latest price at 14.680, total market value of 14.245 billion, year-to-date increase of 319.43% [2] - 帝王国际投资: Increased by 5.50%, latest price at 0.115, total market value of 0.0213 billion, year-to-date increase of 155.56% [2] - 映恩生物-B: Increased by 5.00%, latest price at 336.000, total market value of 29.58 billion, year-to-date increase of 255.18% [2] - 基石药业-B: Increased by 4.66%, latest price at 7.190, total market value of 10.612 billion, year-to-date increase of 212.61% [2] - 三叶草生物-B: Increased by 4.39%, latest price at 2.140, total market value of 2.776 billion, year-to-date increase of 787.97% [2] - 百奥塞图-B: Increased by 3.86%, latest price at 24.220, total market value of 9.673 billion, year-to-date increase of 184.94% [2] - 来凯医药-B: Increased by 3.71%, latest price at 14.540, total market value of 6.49217 billion, year-to-date increase of 55.18% [2] - 君实生物: Increased by 3.29%, latest price at 27.600, total market value of 28.337 billion, year-to-date increase of 138.34% [2] - MIRXES-B: Increased by 3.26%, latest price at 72.900, total market value of 20.145 billion, year-to-date increase of 212.88% [2]

Core Viewpoint - The China Securities Regulatory Commission has approved the A-share issuance registration application for the company on October 15, 2025 [1] Group 1 - The company is set to issue A-shares following the approval from the regulatory authority [1]

Core Viewpoint - The company, Baiaosaitu-B (02315.HK), has received approval from the China Securities Regulatory Commission (CSRC) for its A-share issuance registration application, effective October 15, 2025 [1] Group 1 - The approval marks a significant milestone for the company in its efforts to expand its capital base through A-share issuance [1] - The registration approval is expected to enhance the company's financial flexibility and support its growth strategies [1]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has successfully registered its IPO on the Sci-Tech Innovation Board, marking a significant milestone for the company in its growth trajectory [1] Company Overview - Established in 2009, Baiaosaitu is a preclinical CRO and biotechnology company [1] - The company offers various innovative animal models and preclinical pharmaceutical research and development services based on its proprietary gene editing technology [1] Technology and Services - Baiaosaitu utilizes its self-developed RenMice fully human antibody mouse platform, which includes multiple series such as RenMab, RenLite, RenNano, RenTCR, and RenTCR-mimic [1] - The platform targets nearly a thousand potential drug targets in the human body for large-scale drug discovery and development [1] - The company has plans to transfer, license, or co-develop promising antibody molecules [1] IPO Journey - The IPO application for Baiaosaitu was accepted on June 20, 2023, and the company passed the review on September 24, 2023 [1] - The registration for the IPO was submitted on September 26, 2023 [1]

Core Viewpoint - The China Securities Regulatory Commission has approved the A-share issuance registration application for Baiaosaitu-B (02315) on October 15, 2025 [1] Group 1 - The approval marks a significant step for the company in accessing the A-share market [1]

（股份代號：2315） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. A股發行註冊獲中證監批准之公告 本公告由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）遵照香港聯合交易所 有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及證券及期貨條例（香港法 例第571章）第XIVA部的內幕消息條文（定義見上市規則）而發出。 茲提述本公司日期為2023年3月6日、2023年3月15日、2023年6月20日及2025年9 月17日及2025年9月24日的公告及日期為2023年3月31日的通函，當中載有（其中 包括）建議首次公開發行A股（「建議A股發行」）並在上海證券交易所（「上交所」） 科創板上市的相關事宜。除另有界定者外，本公告所用詞彙與上述公告及通函所 界定者具有相同涵義。 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) registration application of Bai Aosai Tu (Beijing) Pharmaceutical Technology Co., Ltd. for listing on the Sci-Tech Innovation Board [1] Company Summary - Bai Aosai Tu is set to launch its IPO, indicating a significant step towards raising capital for its operations and growth [1] - The approval from the CSRC reflects the company's compliance with regulatory requirements and its readiness for public investment [1] Industry Summary - The approval of IPOs in the biotech sector, such as Bai Aosai Tu, highlights the growing interest and investment potential in the pharmaceutical technology industry in China [1] - The listing on the Sci-Tech Innovation Board is part of China's broader strategy to support innovative companies and enhance the development of the biotech industry [1]